Chronic spontaneous urticaria (CSU) affects more than 80 million people worldwide – and the trend is increasing. The level of suffering among patients is very high. With the new CRUSE control app, disease activity and control can be optimally monitored, the next doctor’s appointment can be perfectly prepared and treatment can be significantly improved. The app was developed by UCARE and a team of experts from the Institute for Allergy Research at the Berlin Charité.